Research Center for Functional Genomics, Biomedicine & Translational Medicine, Iuliu Hatieganu University of Medicine & Pharmacy, 23 Marinescu Street, 400337, Cluj-Napoca, Romania.
Department of Hematology, Iuliu Hatieganu University of Medicine & Pharmacy, 21 December Boulevard, 400124, Cluj-Napoca, Romania.
Biomark Med. 2020 Apr;14(6):451-458. doi: 10.2217/bmm-2019-0510. Epub 2020 Apr 9.
Chronic myelogenous leukemia (CML) is a hematological malignancy characterized by the excessive proliferation of myeloid progenitors. In the case of CML, these extracellular vesicles (EVs) were shown to communicate with hematopoietic stem cells, mesenchymal stem cells, myeloid derived suppressor cells and endothelial cells determining a beneficial microenvironment for the CML clone. Moreover, as these EVs are marked through BCR-ABL1, they were shown to be useful in clinical research in determining the grade of molecular remission with further studies being needed to determine if they are better or worse at predicting CML relapse. More than this, we consider BCR-ABL1-positive EVs to represent only a stepping-stone for other malignancies that also present fusion genes that are loaded in EVs.
慢性髓系白血病（CML）是一种血液系统恶性肿瘤，其特征是髓系前体细胞的过度增殖。在 CML 的情况下，这些细胞外囊泡（EVs）被证明可以与造血干细胞、间充质干细胞、髓源性抑制细胞和内皮细胞进行通讯，从而为 CML 克隆决定一个有益的微环境。此外，由于这些 EVs 通过 BCR-ABL1 标记，它们被证明在临床研究中对于确定分子缓解的程度很有用，进一步的研究需要确定它们是否比其他方法更好或更差地预测 CML 复发。不仅如此，我们还认为 BCR-ABL1 阳性 EVs 只是其他也存在融合基因并加载在 EVs 中的恶性肿瘤的一个起点。
